SESSION TYPE: Arrhythmias Posters
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: Little is known about whethher the recent use of anticoagulant/antiplatelet agent for atrial fibrillation(AF) in outpatient is guided by risk stratification in new anticoagulant prevailing day.
METHODS: 172 patients with AF, who was followed at our clinic between Jan 2011 and Dec 2011, were investigated on recent anticoagulant/antiplaelet use stratified by CHADS2 score. The decision for anticoagulant/ antiplatelet use was made by the attending physicians at outpatient(2 cardiology, 1pulmonology, 1general). No intervention to guide anticoagulant orantiplaelet therapy was made.
RESULTS: The age was 76.4(SD 22.5%), 29.0% female, 23.3% of patients were paroxymal AF, 76.6% were persistent/permanent AF. The prevalence of clinical conditions and associated comorbidities in CHADS"2 score were as follows: left ventricular dysfunction(27.2%), left atrial enlargement(27.7%), ischemic heart disease(7.5%), congenital heart disease(3.5%),cardiomyopathy(4.0%), hypertension(61.3%), age≧75(48.0%), diabetes(21.4%),,stoke/transient ischemic attack(11.6%). The mean CHADS score was 2.2(SD 1.1). The percentage of patients with CHADS2 score from 0 to 6 were 4.7%, 20.3%, 35.4%, 23.8%, 7.3%, 4.3% and 1.7%,respectively. The anticoagulat use was 67.4%, antiplatelet 9.2% and no use of both 23,3%. The percentage of patients on anticoagulant use with CHADS2 score from 0 to 6 were 37, 5%, 65,7%, 65.6%, 82.9%,68.8%, 50.0% and 33.3%, respectively.The proportion of antiplatelet use by increasing CHADS2 score were 5.9%, 29.4%, 35.3%, 17.6%, 5.9%,5.9% and nonetimable,respectively.
CONCLUSIONS: The anticoagulant agent was used on low risk AF patients, whereas thier use in patients with high risk was low or not used.
CLINICAL IMPLICATIONS: The results is useful to improve appropriate anticoagulant use and further patient education.
DISCLOSURE: The following authors have nothing to disclose: Nobuyki Anzai, Hiroko Anzai, Rieko Mitobe, Makiko Anzai, Kei Goto
No Product/Research Disclosure InformationAnzai-Furuya Clinic, Oyam, Japan